In Reply
- Jennifer R. Brown, M.D., Ph.D., Dana-Farber Cancer Institute, 44 Binney St. D1B18, Boston, Massachusetts 02115, USA. Telephone: 617-632-4894; Fax: 617-582-7909 e-mail: jbrown2{at}partners.org
- Received June 28, 2006.
- Accepted July 10, 2006.
In their letter, Gruber et al. [1] present data on the significant risk for lymphoma development in patients with lymphomatoid papulosis. Given this risk, they conclude that treatments are needed to prevent the development of systemic lymphoma. However, it should be noted that no currently available treatment for lymphomatoid papulosis has been shown to alter the natural history of the disease [2]. Furthermore, by analogy to indolent B-cell lymphomas, therapy does not appear to alter the risk for transformation to a more aggressive histology [3]. Unfortunately, therefore, more aggressive therapy of lymphomatoid papulosis may not prevent the development of aggressive lymphoma.
Disclosure of Potential Conflicts of Interest
The author indicates no potential conflicts of interest.
- © AlphaMed Press
